Did you know…
Saccharomyces boulardii CNCM I-745 was the world's first probiotic drug to hit the market.
A BREAKTHROUGH HEALTH INNOVATION
From a Life-Changing Discovery to a Gold Standard
In 1923, during an expedition in Southeast Asia, French microbiologist Henri Boulard made a chance discovery. He observed locals drinking a special tea made from the skins of two tropical fruits, litchis and mangosteens, to alleviate stomach problems. Through his research, Boulard identified a yeast strain, Saccharomyces boulardii CNCM I-745, as the key ingredient behind the tea's remarkable gut beneficial properties.
Years later, in 1953, Saccharomyces boulardii CNCM I-745, also known as Bioflor®, was successfully introduced into commercial use.
Today, Bioflor® has become the gold standard in gut health management1,2 and is widely used in association with antibiotics and on various other occasions, making it the most-sold probiotic drug worldwide. It is suitable for individuals of all ages, from children to adults. With its natural origin and 40 years of pharmacovigilance, we prioritize the safety and well-being of our consumers above all.
Our mission is to empower you to take charge of your sustainable health by promoting a balanced gut microbiota. Let’s embark on this journey together today!
Years later, in 1953, Saccharomyces boulardii CNCM I-745, also known as Bioflor®, was successfully introduced into commercial use.
Today, Bioflor® has become the gold standard in gut health management1,2 and is widely used in association with antibiotics and on various other occasions, making it the most-sold probiotic drug worldwide. It is suitable for individuals of all ages, from children to adults. With its natural origin and 40 years of pharmacovigilance, we prioritize the safety and well-being of our consumers above all.
Our mission is to empower you to take charge of your sustainable health by promoting a balanced gut microbiota. Let’s embark on this journey together today!
Key Facts and Figures of Success3
No.1 Recommended
in Most International Guidelines4
76% Worldwide Coverage
95+ Countries Operated
70+ Years in the Market
130+ Clinical Trials
366 Million
Patients Treated since 1980
Reference:
- McFarland, LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World journal of gastroenterology: WJG. 2010; 16(18): 2202.
- More MI, and Swidsinski, A. Clinical and experimental gastroenterology. 2015; 8: 237.
- Data on file. Biocodex.
- Szajewska H, et al. Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 2023 Feb 1;76(2):232-247. doi: 10.1097/MPG.0000000000003633.
AD-20240716-01